All In Biotech

NDA 208051 · Puma Biotech

Nerlynx

Neratinib Maleate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 17, 2017

Approved uses

6

Original approval plus efficacy supplements

Registered trials

92

5 Phase 3, 21 recruiting

FAERS reports

2,319

1,373 serious, 364 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 2, 2026.

NERLYNX is a kinase inhibitor indicated: As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. ( 1.1 ) In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. ( 1.2 ) 1.1 Extended Adjuvant Treatment of Early-Stage Breast Cancer NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy [see Clinical Studies ( 14.1 )] . 1.2 Advanced or Metastatic Breast Cancer NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting [see Clinical Studies ( 14.2 )] .

Mechanism: Neratinib is an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor receptor (EGFR), HER2, and HER4. In vitro , neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo , oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NERLYNX · NERATINIB MALEATE EQ 40MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Neratinib" as an intervention, any sponsor and status, largest first.

All 92 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,262
  • nausea557
  • fatigue474
  • off label use414
  • vomiting317
  • constipation279
  • decreased appetite257
  • death199
  • disease progression157
  • dehydration148
  • weight decreased139
  • abdominal pain119

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20093
201023
201110
201213
201316
20148
20155
20161
2017143
2018739
2019241
2020255
2021280
2022170
2023147
2024124
202584
202657

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nerlynx (Neratinib Maleate)

2024 spending

$38.4M

Beneficiaries

466

2,103 claims

Per beneficiary

$82,403

$121.16 per unit

View as table
YearSpending
2020$42,196,972
2021$30,227,649
2022$31,488,068
2023$36,541,269
2024$38,400,021

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 88 on PubMed

Sponsor: Puma Biotech

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.